Allergan conducting Phase III program for Posurdex in Korea

Published: 2006-11-01 06:57:00

Updated: 2006-11-01 06:57:00

Allergan, the U.S.-based global health care company, is currently conducting two Phase III clinical programs in 100 hospitals worldwide with Posurdex, the first biodegradable ocular implant, focusing on macular edema associated with diabetes and other conditions, according to Allergan Korea.

I...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK